

LISTING OF CLAIMS

1. (Presently Amended) A pharmaceutical composition which has a healing action and which comprises:

(1) at least one dextran derivative of the general formula $DMC_aB_bSu_c$ in which:

D represents a polysaccharide chain, ~~preferably consisting of linked glucoside units,~~

MC represents methylcarboxylate groups,

B represents carboxymethylbenzylamide groups,

Su represents sulfate groups (sulfation of the free hydroxyl functions carried by the glucoside units),

a, b and c represent the degree of substitution (ds), expressed with respect to the number of free hydroxyl functions in a glucoside unit of the dextran, with MC, B and Su groups, respectively; with a being ≥ 0.6 , b ≥ 0.1 and c being equal to 0 or between 0.1 and 0.5,

which products exhibit a homogeneity in the distribution of the chain sizes which is illustrated by an elution profile of the symmetrical Gaussian type in high-performance steric exclusion chromatography and homogeneity in the distribution of the charged chemical groups which is illustrated by an elution profile having a single symmetrical peak in low-pressure ion exchange chromatography,

REPLY AND AMENDMENT October 30, 2003
U.S. Serial No. 10/020,044
LISTING OF CLAIMS

(2) and also at least one pharmaceutically acceptable excipient, with said dextran derivative being present at a unit dose of between 0.1 and 50 mg.

2. (Presently Amended) A process for preparing a medicament having a healing action comprising the step of using~~The use of~~ the pharmaceutical composition as claimed in claim 1~~for preparing a medicament having a healing action.~~

3. (Presently Amended) A process for preparing a medicament having an action on the healing of the gastric mucosa comprising the step of using~~The use of~~ the pharmaceutical composition as claimed in claim 1~~for preparing a medicament having an action on the healing of the gastric mucosa.~~

4. (Presently Amended) The process~~the use~~ as claimed in claim 3, characterized in that the unit dose of said dextran derivative is between 1.5 and 10 mg.

5. (Presently Amended) The process~~the use~~ as claimed in claim 3 or claim 4, characterized in that said pharmaceutical composition is present in the form of a gel, a gastric dressing, a syrup or a potable solution.

6. (Presently Amended) The process~~use~~ as claimed in any one of claims 3 to 5, characterized in that said dextran derivative is enclosed in a vector.

7. (Presently Amended) The process~~use~~ as claimed in any one of claims 3 to 6, characterized in that said pharmaceutical composition is adapted for oral administration.

8. (Presently Amended) A process for preparing a medicament having an action on muscle healing comprising the step of

REPLY AND AMENDMENT October 30, 2003
U.S. Serial No. 10/020,044
LISTING OF CLAIMS

~~using~~The use of the pharmaceutical composition as claimed in claim 1 ~~for preparing a medicament having an action on muscle healing.~~

9. (Presently Amended) The process as claimed in claim 8, characterized in that the unit dose of said dextran derivative is between 0.5 and 50 mg.

10. (Presently Amended) The process as claimed in claim 8 or claim 9, characterized in that said pharmaceutical composition is present in the form of a gel, an ointment or an isotonic solution.

11. (Presently Amended) The process as claimed in any one of claims 8 to 10, characterized in that said pharmaceutical composition is adapted to administration by local external application or by the parenteral route.

12. (Presently Amended) ~~The use of~~A process for preparing a medicament having an action on ocular healing comprising the step of using the pharmaceutical composition as claimed in claim 1 ~~for preparing a medicament having an action on ocular healing.~~

13. (Presently Amended) The process as claimed in claim 12, characterized in that the unit dose of said dextran derivative is between 0.1 and 10 mg.

14. (Presently Amended) The process as claimed in claim 12 or claim 13, characterized in that said pharmaceutical composition is present in the ~~from~~form of eye drops or an ophthalmic ointment.

REPLY AND AMENDMENT October 30, 2003
U.S. Serial No. 10/020,044
LISTING OF CLAIMS

15. (Original) A pharmaceutical composition which has an action on skin healing, which is adapted to topical administration and which comprises:

(1) at least one dextran derivative of the general formula $DMC_aB_bSu_c$ in which:

D represents a polysaccharide chain, ~~preferably consisting of linked glucoside units,~~

MC represents methylcarboxylate groups,

Su represents sulfate groups (sulfation of the free hydroxyl functions carried by the glucoside units),

a, b and c represent the degree of substitution (ds), expressed with respect to the number of free hydroxyl functions in a glucoside unit of the dextran, with MC, B and Su groups, respectively; with a being ≥ 0.6 , b being ≥ 0.1 and c being equal to 0 or between 0.1 and 0.5,

which products exhibit a homogeneity in the distribution of the chain sizes which is illustrated by an elution profile of the symmetrical Gaussian type in high-performance steric exclusion chromatography and a homogeneity in the distribution of the charged chemical groups which is illustrated by an elution profile having a single symmetrical peak in low-pressure ion exchange chromatography,

(2) and also at least one pharmaceutically acceptable excipient,

with said dextran derivative being present at a concentration of less than 10% (by weight/volume).

REPLY AND AMENDMENT October 30, 2003
U.S. Serial No. 10/020,044
LISTING OF CLAIMS

16. (Presently Amended) ~~The use of~~ A process for preparing a medicament which has an action on skin healing and which is intended to be administered topically comprising the step of using the pharmaceutical composition as claimed in claim 15 ~~for preparing a medicament which has an action on skin healing and which is intended to be administered topically.~~

17. (Presently Amended) The ~~process~~ use as claimed in claim 16, characterized in that said pharmaceutical composition is present in the form of a paste, an ointment, an aqueous liquid, an oily liquid, an aqueous gel, an oily gel, an aerosol, a foam, a microemulsion, a multiple emulsion, liposomes or nanoparticles.

18. (Presently Amended) A pharmaceutical composition which has an anticomplementary action and which comprises:

(1) at least one dextran derivative of the general formula $DMC_aB_bSu_c$ in which:

D represents a polysaccharide chain, ~~preferably consisting of linked glucoside units,~~

MC represents methylcarboxylate groups,

B represents carboxymethylbenzylamide groups,

Su represents sulfate groups (sulfation of the free hydroxyl functions carried by the glucoside units),

a, b and c represent the degree of substitution (ds), expressed with respect to the number of free hydroxyl functions in a glucoside unit of the dextran, with MC, B and

REPLY AND AMENDMENT October 30, 2003
U.S. Serial No. 10/020,044
LISTING OF CLAIMS

Su groups, respectively; with a being ≥ 0.3 , b being ≥ 0.1 and c being equal to 0 or between 0.1 and 0.4,

which products exhibit a homogeneity in the distribution of the chain sizes which is illustrated by an elution profile of the symmetrical Gaussian type in high-performance steric exclusion chromatography and a homogeneity in the distribution of the charged chemical groups which is illustrated by an elution profile having a single symmetrical peak in low-pressure ion exchange chromatography,

(2) and also at least one pharmaceutically acceptable excipient,

with said dextran derivative being present at a unit dose of between 5 and 30 mg.

19. (Presently Amended) ~~The use of~~ A process for preparing a medicament having an anticomplementary action comprising the step of using the pharmaceutical composition as claimed in claim 18 ~~for preparing a medicament having an anticomplementary action.~~

20. (Presently Amended) The ~~use~~ process as claimed in claim 19, characterized in that said pharmaceutical composition is present in the form of an isotonic solution.

21. (Original) A dressing, characterized in that it is soaked with pharmaceutical composition as claimed in claim 15.

22. (New) The pharmaceutical composition as claimed in claim 1 wherein said polysaccharide chain consists of linked glucoside units.

REPLY AND AMENDMENT October 30, 2003
U.S. Serial No. 10/020,044
LISTING OF CLAIMS

23. (New) The pharmaceutical composition as claimed in claim 15 wherein said polysaccharide chain consists of linked glucoside units.

24. (New) The pharmaceutical composition as claimed in claim 18 wherein said polysaccharide chain consists of linked glucoside units.